2024-09-01 - Analysis Report
## ABT Stock Analysis Report

**Company Overview:** Abbott Laboratories (ABT) is a global healthcare company specializing in pharmaceuticals, medical devices, and nutrition products.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** ABT's cumulative return is 41.96%, while VOO's is 89.66%. This indicates that ABT has lagged behind the S&P 500 by a significant margin. 
* **Relative Divergence:**  The current relative divergence is -15.65, which means ABT is underperforming VOO by 15.65%.  The relative divergence indicates that ABT is currently in the 18.89th percentile of its historical performance range compared to VOO. This suggests that ABT's performance relative to the market has been historically worse than the current position.

**2. Recent Price Movement:**

* **Closing Price:** $113.27
* **5-day Moving Average:** $112.95
* **20-day Moving Average:** $110.90
* **60-day Moving Average:** $106.71

This indicates a recent upward trend in ABT's price, with the closing price above all three moving averages.

**3. Technical Indicators:**

* **RSI:** 82.52
* **PPO:** 0.03
* **Delta_Previous_Relative_Divergence:** 7.26 

The RSI value suggests that ABT is currently in overbought territory, indicating potential for a short-term correction. The PPO indicates a slight upward momentum, but the overbought RSI suggests caution. The positive Delta_Previous_Relative_Divergence indicates a recent improvement in relative performance compared to previous periods, but it is important to note that the overall relative performance is still lagging behind the S&P 500.

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue |
|-------------|-------|---------|
| 2024-07-31 | 0.74  | 10.38 B$ |
| 2024-05-02 | 0.70  | 9.96 B$ |
| 2023-11-01 | 0.82  | 10.14 B$ |
| 2023-08-03 | 0.79  | 9.98 B$ |
| 2024-07-31 | 0.79  | 9.98 B$ |

The most recent earnings report (2024-07-31) shows that ABT slightly exceeded analyst expectations for EPS and revenue. However, the recent earnings performance has been relatively flat, with EPS and revenue exhibiting modest growth. 

**5. Overall Analysis:**

ABT's current performance is lagging behind the S&P 500, with a significant relative divergence. While the recent price movement suggests upward momentum, the technical indicators, particularly the RSI, suggest potential for a short-term correction. While the most recent earnings results slightly beat expectations, the overall trend shows modest growth. Therefore, investors should be cautious and monitor ABT's performance closely.

**6. Recommendation:** 

Based on the analysis, ABT's current performance is underwhelming. While the recent price movement and earnings beat indicate potential for short-term growth, the technical indicators and long-term underperformance relative to the market suggest a wait-and-see approach. Investors may consider adding ABT to their portfolio only after further observation and analysis of its performance and future prospects. 
